Athersys Quote - ATHX

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

0.1018

Bid

0.101

Offer

0.104

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

1.831M

Previous Close

0.1018

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

17,986,000

Dividend Yield

PE Ratio

-0.02

Earnings Per Share (EPS)

-4.03

Revenue

5.33M

Net Profit

-72.53M

Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are foc... Athersys Inc is a biotechnology company. It is focused on developing novel and proprietary therapies in the areas where there is an unmet medical need, particularly in the regenerative medicine area. The firm's main product is Multistem cell therapy. Its current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders and certain pulmonary conditions. Its revenue has been derived from corporate collaborations, license agreements, and government grants. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.athersys.com

Headquarters

Wilmington, Delaware, USA

Founded

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives

Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announces it has...

Form 8-K - Current report

Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios

The MOU includes $1.5M to $4.5M near term payments plus up to $150M in milestones Athersys, Inc. (Nasdaq: ATHX), a cell therapy and regenerative medicine company developing MultiStem®...

Form 4 - Statement of changes in beneficial ownership of securities

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
PRFXPainReform Ltd	US$ 1.309 (144.67%)	168.32M
NCNCnoco noco Inc	US$ 0.1869 (92.68%)	703.72M
SMCXDefiance Daily Target 2X Long SMCI ETF	US$ 40.2673 (57.79%)	3.24M
ACRSAclaris Therapeutics Inc	US$ 4.9405 (57.34%)	42.01M
SYRSSyros Pharmaceuticals Inc	US$ 0.2806 (41.15%)	247.98M
SLNSilence Therapeutics PLC	US$ 7.04 (-36.12%)	2.32M
AKTXAkari Therapeutics PLC	US$ 1.55 (-32.31%)	223.78k
DFLIDragonfly Energy Holdings Corporation	US$ 0.35 (-30.26%)	2.15M
DMNDamon Inc	US$ 1.72 (-28.63%)	636.91k
QMMMQMMM Holdings Limited	US$ 1.2785 (-26.10%)	3.94M
NCNCnoco noco Inc	US$ 0.1872 (92.99%)	711.03M
SYRSSyros Pharmaceuticals Inc	US$ 0.280672 (41.18%)	248.24M
WBUYWeBuy Global Ltd	US$ 0.1941 (22.00%)	245.43M
SMCISuper Micro Computer Inc	US$ 27.755 (28.85%)	179.41M
PRFXPainReform Ltd	US$ 1.30 (142.99%)	169.67M